{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T21:23:58Z","timestamp":1781731438167,"version":"3.54.5"},"reference-count":24,"publisher":"Norwegian Medical Association","issue":"23\/24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"DOI":"10.4045\/tidsskr.16.1092","type":"journal-article","created":{"date-parts":[[2017,12,12]],"date-time":"2017-12-12T08:50:51Z","timestamp":1513068651000},"source":"Crossref","is-referenced-by-count":8,"title":["Progressive multifocal leukoencephalopathy"],"prefix":"10.4045","volume":"137","author":[{"given":"Karl Bj\u00f8rnar","family":"Alstadhaug","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell-Morten","family":"Myhr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6970-6728","authenticated-orcid":false,"given":"Christine Hanssen","family":"Rinaldo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","published-online":{"date-parts":[[2017,12,12]]},"reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"Hirsch\u00a0HH, Kardas\u00a0P, Kranz\u00a0D et al. The human JC polyomavirus (JCPyV): virological background and clinical implications. APMIS 2013; 121: 685\u2013727. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23781977&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111%2Fapm.12128","DOI":"10.1111\/apm.12128"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Engsig\u00a0FN, Hansen\u00a0AB, Omland\u00a0LH et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis 2009; 199: 77\u201383. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19007313&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1086%2F595299","DOI":"10.1086\/595299"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Tan\u00a0CS, Koralnik\u00a0IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010; 9: 425\u201337. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20298966&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS1474-4422(10)70040-5","DOI":"10.1016\/S1474-4422(10)70040-5"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Elphick\u00a0GF, Querbes\u00a0W, Jordan\u00a0JA et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 2004; 306: 1380\u20133. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15550673&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1126%2Fscience.1103492","DOI":"10.1126\/science.1103492"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Alstadhaug\u00a0KB, Croughs\u00a0T, Henriksen\u00a0S et al. Treatment of progressive multifocal leukoencephalopathy with interleukin 7. JAMA Neurol 2014; 71: 1030\u20135. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24979548&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1001%2Fjamaneurol.2014.825","DOI":"10.1001\/jamaneurol.2014.825"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Amend\u00a0KL, Turnbull\u00a0B, Foskett\u00a0N et al. Incidence of progressive multifocal leukoencephalopathy in patients without HIV. Neurology 2010; 75: 1326\u201332. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20938025&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1212%2FWNL.0b013e3181f73600","DOI":"10.1212\/WNL.0b013e3181f73600"},{"key":"ref=7","unstructured":"Biogen. TYSABRI PML Safety Update. https:\/\/medinfo.biogen.com\/secure\/download?doc=workspace%3A%2F%2FSpacesStore%2Fded9df8f-d785-444a-ae89-888bef72aa7e&type=pmldoc&path=null&dpath=null&mimeType=null&Continue=Continue (30.8.2016)."},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Hohlfeld\u00a0R, Dornmair\u00a0K, Meinl\u00a0E et al. The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets. Lancet Neurol 2016; 15: 198\u2013209. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26724103&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS1474-4422(15)00334-8","DOI":"10.1016\/S1474-4422(15)00334-8"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Hohlfeld\u00a0R, Dornmair\u00a0K, Meinl\u00a0E et al. The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research. Lancet Neurol 2016; 15: 317\u201331. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26724102&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS1474-4422(15)00313-0","DOI":"10.1016\/S1474-4422(15)00313-0"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Alstadhaug\u00a0KB, Fykse Halstensen\u00a0R, Odeh\u00a0F. Progressive multifocal leukoencephalopathy in a patient with systemic mastocytosis treated with cladribine. J Clin Virol 2017; 88: 17\u201320. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28095350&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.jcv.2016.12.005","DOI":"10.1016\/j.jcv.2016.12.005"},{"key":"ref=11","unstructured":"Biogen. Retningslinjer for h\u00e5ndtering av pasienter med multippel sklerose som behandles med Tysabri. Versjon 16: 06\/2016. http:\/\/www.felleskatalogen.no\/medisin\/dokument\/tysabri-retningslinjer-helsepersonell.pdf\u00a0(26.8.2016)."},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Borchardt\u00a0J, Berger\u00a0JR. Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler Relat Disord 2016; 8: 145\u201350. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=27456891&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.msard.2016.03.005","DOI":"10.1016\/j.msard.2016.03.005"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Winkelmann\u00a0A, Loebermann\u00a0M, Reisinger\u00a0EC et al. Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol 2016; 12: 217\u201333. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26943779&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038%2Fnrneurol.2016.21","DOI":"10.1038\/nrneurol.2016.21"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Schmedt\u00a0N, Andersohn\u00a0F, Garbe\u00a0E. Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf 2012; 21: 1216\u201320. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22821419&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002%2Fpds.3320","DOI":"10.1002\/pds.3320"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Gold\u00a0R, Radue\u00a0EW, Giovannoni\u00a0G et al. Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. BMC Neurol 2016; 16: 117. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=27461166&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1186%2Fs12883-016-0635-y","DOI":"10.1186\/s12883-016-0635-y"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Giovannoni\u00a0G, Comi\u00a0G, Cook\u00a0S et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010; 362: 416\u201326. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20089960&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMoa0902533","DOI":"10.1056\/NEJMoa0902533"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Molloy\u00a0ES, Calabrese\u00a0LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 2009; 60: 3761\u20135. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19950261&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002%2Fart.24966","DOI":"10.1002\/art.24966"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Hauser\u00a0SL, Bar-Or\u00a0A, Comi\u00a0G et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 2017; 376: 221\u201334. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28002679&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMoa1601277","DOI":"10.1056\/NEJMoa1601277"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Schwab\u00a0N, Ulzheimer\u00a0JC, Fox\u00a0RJ et al. Fatal PML associated with efalizumab therapy: insights into integrin \u03b1L\u03b22 in JC virus control. Neurology 2012; 78: 458\u201367, discussion 465. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22302546&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1212%2FWNL.0b013e3182478d4b","DOI":"10.1212\/WNL.0b013e3182478d4b"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Sahraian\u00a0MA, Radue\u00a0EW, Eshaghi\u00a0A et al. Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis. Eur J Neurol 2012; 19: 1060\u20139. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22136455&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111%2Fj.1468-1331.2011.03597.x","DOI":"10.1111\/j.1468-1331.2011.03597.x"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Pavlovic\u00a0D, Patera\u00a0AC, Nyberg\u00a0F et al. Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther Adv Neurol Disorder 2015; 8: 255\u201373. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26600871&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1177%2F1756285615602832","DOI":"10.1177\/1756285615602832"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"Clifford\u00a0DB, Nath\u00a0A, Cinque\u00a0P et al. A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J Neurovirol 2013; 19: 351\u20138. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23733308&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007%2Fs13365-013-0173-y","DOI":"10.1007\/s13365-013-0173-y"},{"key":"ref=23","doi-asserted-by":"crossref","unstructured":"Jamilloux\u00a0Y, Kerever\u00a0S, Ferry\u00a0T et al. Treatment of Progressive Multifocal Leukoencephalopathy With Mirtazapine. Clin Drug Investig 2016; 36: 783\u20139. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=27401779&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007%2Fs40261-016-0433-8","DOI":"10.1007\/s40261-016-0433-8"},{"key":"ref=24","doi-asserted-by":"crossref","unstructured":"Sospedra\u00a0M, Schippling\u00a0S, Yousef\u00a0S et al. Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1. Clin Infect Dis 2014; 59: 1588\u201392. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25214510&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1093%2Fcid%2Fciu682","DOI":"10.1093\/cid\/ciu682"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":["Progredierende multifokal leukoencefalopati"],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T06:48:56Z","timestamp":1781678936000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2017\/12\/klinisk-oversikt\/progredierende-multifokal-leukoencefalopati"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,12]]},"references-count":24,"journal-issue":{"issue":"23\/24","published-online":{"date-parts":[[2017,12,12]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.16.1092","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,12]]}}}